4.2.4 Targeted therapies and immunotherapy
There are many therapies that have a targeted approach. This is an ever-expanding group of therapies, and the multidisciplinary team must be mindful of this field.
Therapies include:
- BCR-ABL-like ALL – addition of tyrosine kinase inhibitor
- bispecific T-cell engagers in bispecific T-cell engagers in ALL – blinatumomab
- antibody-drug conjugate targeting CD33 antigen in AML – gemtuzumab ozogamicin
- antibody-drug conjugates targeting CD22 antigen in ALL – inotuzumab ozogamicin
- chimeric antigen receptor (CAR) T-cells – genetically engineered T-cells to produce a receptor that recognises a cancer target such as CD19 antigen in B-cell ALL.